NKGen Biotech to Present Long-Term Follow-Up of Troculeucel in Moderate Alzheimer’s Disease at CTAD 2026

(OTC:NKGN) NKGen Biotech, Inc. announced it will present a poster at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, which will be held from November 16-19, 2026, in Boston, Massachusetts, and virtually. The poster will describe observations from a patient with moderate Alzheimer’s disease who received troculeucel in the Company’s Phase 1 study and subsequently enrolled in an open-label extension study (NCT07228078), receiving an additional 12 months of treatment. The presentation will explore the patient’s cognitive outcomes over the extended treatment period. The poster is titled 'Long-Term Cognitive Benefit of Troculeucel NK Cell Therapy in a Patient With Moderate Alzheimer’s Disease: A Single-Subject Analysis (P062)' and will be presented during Poster Session 1, from Monday, November 16, 2026, at 2:00 p.m. ET through Tuesday, November 17, 2026, at 5:30 p.m. ET. Previously disclosed data for troculeucel in Alzheimer’s disease and solid tumors are available on the Scientific Publications page of the Company’s website. Company news releases regarding troculeucel clinical trial updates and regulatory developments are available on the Company’s News page. Troculeucel is described as a novel cell-based, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (INN) for SNK01 assigned by the World Health Organization (WHO). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market. NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA.